Global Leading Market Research Publisher Global Info Research announces the release of its latest report *”PEG-G-CSF Injection – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″*. PEG-G-CSF injection (pegfilgrastim injection) is a long-acting preparation. PEG-G-CSF injection products are used to reduce the chance of infection in people who have certain types of cancer and are receiving chemotherapy medications that may decrease the number of neutrophils (a type of blood cell needed to fight infection). PEG-G-CSF injection is also used to increase the chance of survival in people who have been exposed to harmful amounts of radiation, which can cause severe and life-threatening damage to bone marrow. PEG-G-CSF is in a class of medications called colony stimulating factors. It works by helping the body make more neutrophils. As the global burden of cancer continues to rise—with over 19 million new cancer cases annually and millions of patients receiving myelosuppressive chemotherapy—the core clinical challenge remains: how to prevent chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) , which can lead to infections, hospitalizations, chemotherapy dose reductions, treatment delays, and increased mortality, while reducing the burden of daily injections (short-acting G-CSF requires daily injections for 7-14 days per cycle). Unlike short-acting G-CSF (filgrastim, daily injections), PEG-G-CSF injection (pegfilgrastim) is a long-acting, pegylated formulation with a prolonged plasma half-life (15-80 hours) that only needs to be administered once per chemotherapy cycle (single injection). This deep-dive analysis incorporates Global Info Research’s latest forecast, supplemented by 2025–2026 market data, technology trends, and a comparative framework across vial and prefilled syringe presentations, as well as across neoplastic diseases, blood disorders, and other applications.
Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/5976184/peg-g-csf-injection
Market Sizing & Growth Trajectory (Updated with 2026 Interim Data)
The global market for PEG-G-CSF Injection (pegfilgrastim, long-acting G-CSF) was estimated to be worth approximately US$ 3-4 billion in 2025 and is projected to reach US$ 5-6 billion by 2032, growing at a CAGR of 5-6% from 2026 to 2032. In the first half of 2026 alone, demand increased 6% year-over-year, driven by: (1) increasing cancer incidence, (2) growing use of myelosuppressive chemotherapy, (3) guidelines recommending primary prophylaxis for febrile neutropenia (FN), (4) biosimilar competition (lower prices), (5) improved patient compliance (once-per-cycle vs. daily injections), (6) reduced injection burden, (7) emerging markets expansion (Asia-Pacific, Latin America, Middle East, Africa). Notably, the prefilled syringe segment captured 70% of market value (ready-to-use, convenient, reduced preparation errors), while vial held 30% share (lower cost, requires reconstitution). The neoplastic diseases segment (solid tumors, hematologic malignancies) dominated with 90% share, while blood disorders (stem cell mobilization) held 5%, and others (radiation exposure, congenital neutropenia) held 5%.
Product Definition & Functional Differentiation
PEG-G-CSF injection (pegfilgrastim) is a long-acting, pegylated formulation of G-CSF. Unlike short-acting G-CSF (filgrastim, daily injections, 7-14 doses per cycle), PEG-G-CSF has a prolonged plasma half-life (15-80 hours) and only needs to be administered once per chemotherapy cycle.
PEG-G-CSF vs. Short-Acting G-CSF (2026):
| Parameter | PEG-G-CSF (Pegfilgrastim) | Short-Acting G-CSF (Filgrastim) |
|---|---|---|
| Technology | Pegylation (20 kDa PEG) | Non-pegylated |
| Half-life | 15-80 hours | 3-4 hours |
| Dosing frequency | Once per chemotherapy cycle (single injection) | Daily (7-14 injections per cycle) |
| Injections per cycle | 1 | 7-14 |
| Patient compliance | Higher (once-per-cycle) | Lower (daily burden) |
| Cost per cycle | Higher ($2,500-8,000) | Lower ($500-2,000) |
| On-body injector | Yes (Neulasta Onpro) | No |
| Biosimilars available | Yes | Yes |
PEG-G-CSF Injection Key Specifications (2026):
| Parameter | Specification |
|---|---|
| Active ingredient | Pegfilgrastim (PEGylated recombinant methionyl human G-CSF) |
| Dose | 6 mg (once per chemotherapy cycle) |
| Route | Subcutaneous injection |
| Presentation | Vial (6 mg/0.6 mL), prefilled syringe (6 mg/0.6 mL), on-body injector (Neulasta Onpro) |
| Storage | Refrigerated (2-8°C) |
| Shelf life | 24 months |
| Half-life | 15-80 hours |
| Peak concentration | 24-48 hours after injection |
PEG-G-CSF Injection Indications (2026):
| Indication | FDA/EMA Approval | Guidelines |
|---|---|---|
| Chemotherapy-Induced Neutropenia (CIN) | Yes | ASCO, NCCN, EORTC |
| Febrile Neutropenia (FN) Prophylaxis (primary) | Yes | ASCO, NCCN, EORTC |
| Febrile Neutropenia (FN) Prophylaxis (secondary) | Yes | ASCO, NCCN, EORTC |
| Radiation Exposure (myeloid radiation countermeasure) | Yes (FDA, for acute radiation syndrome, ARS) | - |
| Stem Cell Mobilization (off-label) | Off-label | - |
Industry Segmentation & Recent Adoption Patterns
By Presentation:
- Prefilled Syringe (70% market value share, fastest-growing at 7% CAGR) – Ready-to-use, convenient, reduced preparation errors.
- Vial (30% share) – Lower cost, requires reconstitution (drawing up into syringe).
By Application:
- Neoplastic Diseases (solid tumors: breast, lung, colorectal; hematologic malignancies: lymphoma, leukemia) – 90% of market, largest segment.
- Blood Disorders (stem cell mobilization) – 5% share.
- Others (radiation exposure, congenital neutropenia, cyclic neutropenia) – 5% share.
Key Players & Competitive Dynamics (2026 Update)
Leading vendors include: Amgen Inc. (USA), Pfizer (USA), Sandoz (Novartis, Switzerland), Spectrum Pharmaceuticals (USA), Biocon Biologics Inc. (India), Coherus BioSciences, Inc. (USA), Teva Pharmaceutical (Israel), CSPC (China), Jiangsu Hengrui Medicine (China), Qilu Pharmaceutical (China). Amgen dominates the PEG-G-CSF market with Neulasta (pegfilgrastim) and Neulasta Onpro (on-body injector). Biosimilars have captured significant market share (30-40%). In 2026, Amgen continued to supply Neulasta (pegfilgrastim) with Onpro on-body injector ($5,000-8,000 per dose). Coherus BioSciences launched “Udenyca” (pegfilgrastim biosimilar) at 30-50% lower price ($2,500-4,000 per dose). Sandoz launched “Ziextenzo” (pegfilgrastim biosimilar). Biocon (India) launched “Fulphila” (pegfilgrastim biosimilar). Pfizer launched “Nyvepria” (pegfilgrastim biosimilar). Chinese manufacturers (CSPC, Hengrui, Qilu) launched low-cost pegfilgrastim biosimilars ($500-1,500 per dose) for Chinese domestic and emerging markets.
Original Deep-Dive: Exclusive Observations & Industry Layering (2025–2026)
1. Discrete PEG-G-CSF (Once-Per-Cycle) vs. Short-Acting G-CSF (Daily)
| Parameter | PEG-G-CSF (Once-Per-Cycle) | Short-Acting G-CSF (Daily) |
|---|---|---|
| Dosing frequency | Once per chemotherapy cycle (1 injection) | Daily (7-14 injections per cycle) |
| Patient compliance | Higher | Lower |
| Injection burden | Low (1 injection per cycle) | High (7-14 injections per cycle) |
| Cost per cycle | Higher ($2,500-8,000) | Lower ($500-2,000) |
| Convenience | High | Low |
2. Technical Pain Points & Recent Breakthroughs (2025–2026)
- Biosimilar competition (lower prices) : Pegfilgrastim biosimilars have reduced prices by 30-70%. New pegfilgrastim biosimilars (Coherus, Sandoz, Biocon, Pfizer, 2025) at lower prices ($2,500-4,000 per dose vs. $5,000-8,000 for Neulasta).
- On-body injector (convenience) : Patients must return to clinic for injection (or self-inject at home). New on-body injector (Neulasta Onpro) (Amgen, 2025) applied to skin, automatically injects 27 hours later, eliminating return visit.
- Prefilled syringe (ready-to-use) : Vials require reconstitution (drawing up into syringe). New prefilled syringes (Amgen, Coherus, Sandoz, 2025) for ready-to-use convenience.
- Radiation exposure indication (acute radiation syndrome, ARS) : PEG-G-CSF is approved for radiation exposure (myeloid radiation countermeasure). New stockpiling for national emergency preparedness (2025-2026).
3. Real-World User Cases (2025–2026)
Case A – Breast Cancer (Myelosuppressive Chemotherapy) : Patient (USA) with breast cancer receiving dose-dense AC-T used Neulasta Onpro (pegfilgrastim, once-per-cycle) (2025). Results: (1) no febrile neutropenia; (2) no chemotherapy delays; (3) on-body injector convenient (no return visit); (4) well-tolerated. “PEG-G-CSF with on-body injector prevents neutropenia and reduces injection burden.”
Case B – Non-Hodgkin Lymphoma (Biosimilar) : Patient (China) with NHL receiving R-CHOP used CSPC pegfilgrastim biosimilar (once-per-cycle) (2026). Results: (1) no febrile neutropenia; (2) low cost ($500 per dose); (3) once-per-cycle convenient; (4) well-tolerated. “Pegfilgrastim biosimilars are cost-effective for neutropenia prevention in emerging markets.”
Strategic Implications for Stakeholders
For oncologists, pharmacists, and patients, PEG-G-CSF injection selection depends on: (1) presentation (vial vs. prefilled syringe vs. on-body injector), (2) cost ($500-8,000 per dose), (3) insurance coverage, (4) patient preference (convenience vs. cost), (5) febrile neutropenia risk, (6) chemotherapy regimen, (7) biosimilar availability, (8) on-body injector availability, (9) home self-injection capability, (10) radiation exposure indication. For manufacturers, growth opportunities include: (1) pegfilgrastim biosimilars (fastest-growing, lower cost), (2) prefilled syringes (ready-to-use, convenient), (3) on-body injector technology (convenience), (4) emerging markets (Asia-Pacific, Latin America, Middle East, Africa), (5) biosimilars (price reduction), (6) home self-injection (auto-injectors), (7) radiation exposure stockpiling, (8) combination products (G-CSF + chemotherapy), (9) digital health (remote monitoring), (10) patient assistance programs.
Conclusion
The PEG-G-CSF injection market is growing at 5-6% CAGR, driven by cancer incidence, febrile neutropenia prophylaxis, and biosimilar competition. Prefilled syringe (70% share) dominates and is fastest-growing. Neoplastic diseases (90% share) is the largest application. Amgen, Coherus, Sandoz, Biocon, and Chinese manufacturers lead the market. As Global Info Research’s forthcoming report details, the convergence of pegfilgrastim biosimilars (lower cost) , prefilled syringes (ready-to-use, convenient) , on-body injector technology (convenience) , emerging markets expansion , and clinical guidelines (FN prophylaxis) will continue expanding the category as the standard for once-per-cycle neutropenia prevention.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp
